Assessing the impact of the substantial equivalence mechanism on the cigarette and cigar markets

Active Project Grant Awarded Last action

Award ID
R01CA298812
Recipient
Awarding agency
Obligated
$1,638,909

Award facts

Completion date 23% complete
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Buffalo, NY 14263, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health Office of the Director awarded Health Research, Inc. Roswell Park Division (doing business as Health Research At Roswell Park) $1.638 million on September 15, 2025, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) to assess the impact of the substantial equivalence mechanism on cigarette and cigar markets.

The recipient will characterize the marketplace for combustible tobacco products by leveraging Nielsen data and laboratory techniques to evaluate the design, contents, and emissions of 15 leading cigarette and cigar subbrands. The research will also assess how consumers differentiate among substantially equivalent products, addressing a gap in regulatory science regarding whether products receiving substantial equivalence determinations based on technical grounds are experienced by consumers in the same way as their predicate products. The study focuses on cigarettes and cigars because both product classes pose the highest established health risks and were well-established markets prior to enactment of the Tobacco Control Act.

Performance occurs in Buffalo, New York, with an ultimate completion date of August 31, 2030. Health Research, Inc. Roswell Park Division is a tax-exempt not-for-profit child organization affiliated with Roswell Park Comprehensive Cancer Center and conducts federally funded biomedical and clinical cancer research as a prime grant recipient.

Description

Abstract
Tobacco product brand/line extensions continue to proliferate as manufacturers seek to maintain or grow their market share. The tobacco control act (TCA) introduced a number of potential pathways for marketing tobacco products, including a substantial equivalence (SE) process. Typically, SE determinations are made by comparing the "new" product to a pre-existing product in terms of design and emissions, with an eye toward whether the new product raises different questions of public health than what was previously on the market. The SE process raises important questions and concerns as to its impacts on the market and on public health. This understudied area of regulatory science could be leveraged by the tobacco industry to retain or attract consumers while avoiding the stricter regulatory standard applied to new products. Under the SE regulatory model in its present form, cigarettes and cigars can continue to evolve through accumulation of small changes and proliferation of line extensions that bear functional similarity to existing products. Notably, human studies are not explicitly required for SE determinations, which raises concerns as to whether a product that receives an SE order on technical grounds is experienced in the same way as the predicate by consumers. Our specific aims are to evaluate the state of the market with respect to SE determinations and assess consumer product differentiation in two combustible tobacco product classes - cigarettes and cigars. These are the products of focus as they are clearly the most associated with health risks, and both of these markets were very well established prior to the TCA. In aim 1 we will characterize the marketplace, leveraging nielsen data and laboratory techniques to assess the design, contents, and emissions of 15 leading subbrands of cigarettes and cigars. In aim 2 we will assess consumer behaviors with respect to substantial equivalence. In study 2.1 we will leverage path data, which contains self-reported brands and sub-brands, to examine trends in the market share of brands. In study 2.2, we will recruit a panel of adults (21+) who currently use one of the 15 leading subbrands of cigarettes and cigars as identified in aim 1. The goal of this study is to examine whether consumers using these products can identify changes to their brand during the course of multiple year follow-up. In aim 3, we assess industry behaviors with respect to substantial equivalence by compiling and integrating SE determinations and other orders posted on FDA's website to examine trends in product characteristics and predicate product usage. A key goal is to determine if there are commonalities to what aspects of product design or emissions are changing, or if there are common predicate products employed. This proposal addresses the product composition and design, behavior, and impact analysis priority research domains.

Transactions

Action Obligated Date
Amendment $822,602
Amendment $0
Original award $816,307

Quick answers

Who received award R01CA298812?

R01CA298812 was awarded to Health Research, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.

How much is award R01CA298812 worth?

$1,638,909 has been obligated on R01CA298812.

Which agency awarded R01CA298812?

National Cancer Institute (National Institutes of Health) awarded R01CA298812, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award